Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial

BACKGROUND: Lapatinib (L) plus trastuzumab (T) improves outcomes for metastatic human epidermal growth factor 2–positive breast cancer and increases the pathologic complete response in the neoadjuvant setting, but their role as adjuvant therapy remains uncertain. METHODS: In the Adjuvant Lapatinib a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Clin Oncol
Hauptverfasser: Piccart-Gebhart, Martine, Holmes, Eileen, Baselga, José, de Azambuja, Evandro, Dueck, Amylou C., Viale, Giuseppe, Zujewski, Jo Anne, Goldhirsch, Aron, Armour, Alison, Pritchard, Kathleen I., McCullough, Ann E., Dolci, Stella, McFadden, Eleanor, Holmes, Andrew P., Tonghua, Liu, Eidtmann, Holger, Dinh, Phuong, Di Cosimo, Serena, Harbeck, Nadia, Tjulandin, Sergei, Im, Young-Hyuck, Huang, Chiun-Sheng, Diéras, Véronique, Hillman, David W., Wolff, Antonio C., Jackisch, Christian, Lang, Istvan, Untch, Michael, Smith, Ian, Boyle, Frances, Xu, Binghe, Gomez, Henry, Suter, Thomas, Gelber, Richard D., Perez, Edith A.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Clinical Oncology 2016
Schlagworte:
ORIGINAL REPORTS
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4872016/
https://ncbi.nlm.nih.gov/pubmed/26598744
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.62.1797
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge